Stable growth of blood products market size

Stable growth of plasma-derived products market size
Plasma-derived products are currently a mainstream product in the world finished pharmaceutical products market, and can be divided into three major categories depending on the source of plasma-derived products: albumin, immunoglobulin and coagulation factors. The current situation of plasma-derived products in China is that the market concentration is already relatively high, because the high barriers to entry in the plasma-derived products industry in China have eliminated many low and mid-range plasma-derived products manufacturers, and the remaining plasma-derived products manufacturers are constantly merging and acquiring. In the future, market concentration will increase further, which is a good thing because the advantages of quality Chinese plasma-derived products manufacturers will be further amplified. 
A brief introduction to plasma-derived products
Blood products are derived from the plasma of healthy people. In China, blood collection and preparation production are two separate and strict systems. After collecting blood plasma, the relevant authorities will transport the tested plasma to blood product manufacturers, and after a series of processing sequences such as: separation, precipitation, and filtration, various blood products are finally formed.
In hospitals plasma products and blood products are used to treat patients who need surgery, for patients with cancer undergoing radiation or chemotherapy, and for patients with burns, liver disease, kidney disease, diabetes and excessive blood loss. The most widely used are immunoglobulin-based products, which are used to improve the patient’s ability to against various diseases.


The origin and development of plasma-derived products and blood products
The earliest development of blood products is to treat patients with excessive blood loss, the earliest mainly used in the battlefield, the development of plasma-derived products market gradually saturated in recent times, the United States as the representative of Europe and the United States blood products development tends to stabilize, China´s plasma-derived products manufacturing enterprises later on to enter a period rapid development, these achievements are due to the policy advantages of China´s blood preparation market and the huge demand of China´s blood preparation market.
As mentioned above, plasma-derived products and plasma preparation are a pharmaceutical field with relatively high entry barriers, and with the increasing internal competitiveness of the Chinese market, Chinese blood preparation and plasma preparation suppliers have to continuously improve their core competitiveness, including the improvement of plasma collection, supply chain upgrade and stuff training. Therefore, although the development of Chinese blood preparation and plasma preparation companies started later than the development of Europe and the United States, Chinese plasma preparation manufacturers are accelerating to catch up in all dimensions, including the improvement of plasma collection, technology upgrade, and the continuous development of sales channels. In the foreseeable future, the Chinese plasma preparation manufacturers will entry to a stable period, and Chinese blood product will be further tested by the international market, and the advantages of Chinese blood preparation suppliers will be amplified.